Dietary proteins contain encrypted peptide sequences with potent biological activity — DPP-IV inhibitors that extend endogenous GLP-1 half-life, ACE inhibitors, opioid peptides. Normal digestion destroys most of them. We engineer the gastrointestinal kinetics to release them intact, at physiologically meaningful concentrations, from ordinary meals.
A 200g serving of beef contains thousands of peptide bonds. Nested within these sequences are fragments — typically 2 to 7 residues — with validated biological activity: DPP-IV inhibitors, ACE inhibitors, opioid ligands, immunomodulatory peptides. The problem is not substrate availability. It is that uncontrolled digestion either fails to liberate these sequences or destroys them through over-hydrolysis.
Pepsin, trypsin, chymotrypsin each have preferred cleavage sites, but their combined action in vivo is governed by stochastic variables — pH drift, unpredictable transit, fluctuating enzyme concentrations, variable food matrix effects — making the yield of any specific bioactive sequence functionally random. Two identical meals can produce radically different peptide profiles.
We convert the gastrointestinal tract from a noisy biochemical environment into a controlled multi-stage reactor — tuning pH, residence time, enzyme exposure, viscosity, and transporter kinetics at each phase — so that the proteolytic cascade preferentially generates and preserves target peptide sequences at concentrations sufficient for physiological effect.
The problem is not supply. It is kinetic control.Pepsin's catalytic efficiency (kcat/Km) for different peptide bonds shifts measurably between pH 2.0 and 3.2. At pH 2.0, the enzyme shows high activity across all hydrophobic residues. At pH 3.0, activity at Phe–X bonds remains high while activity at Leu–X and Trp–X bonds drops 2–4 fold — creating a selectivity window exploitable for targeted cleavage.
PepT1 transports di/tripeptides via H⁺ symport. Transport rate is a function of the transapical proton gradient maintained by NHE3. Luminal pH reduction from 6.5 to 5.5 increases PepT1-mediated uptake of model dipeptides by 3–5 fold. We titrate luminal acidification to maximize target peptide absorption while maintaining mucosal integrity.
CD26/DPP-IV on the jejunal brush border cleaves penultimate-proline peptides including GLP-1(7-36)amide → GLP-1(9-36). Food-derived competitive inhibitors (IPI, VAGTWY) reaching the brush border suppress this cleavage locally — protecting endogenous incretin hormones at their most vulnerable point before portal absorption.
We prioritize targets where food-derived bioactive peptides have published IC₅₀ data, validated mechanisms, and clear physiological endpoints. Each axis has a defined formulation strategy and evidence pathway.
The semaglutide approach floods the system with exogenous GLP-1 receptor agonist. Ours amplifies the endogenous pathway. Protein hydrolysates stimulate GLP-1 secretion from ileal L-cells via CaSR and PepT1-mediated nutrient sensing. Simultaneously, food-derived DPP-IV inhibitory peptides suppress the serine protease that cleaves GLP-1(7-36)amide to inactive GLP-1(9-36) — extending a native half-life of approximately 2 minutes. DPP-IV is expressed both at the intestinal brush border (CD26) and in soluble form in plasma. Food-derived inhibitors act at the gut level before GLP-1 even reaches systemic circulation.
The most validated class in bioactive peptide research. ACE (EC 3.4.15.1) converts angiotensin I to angiotensin II (vasoconstrictor) and degrades bradykinin (vasodilator). Food-derived ACE-i peptides — predominantly proline-rich C-terminal sequences — competitively bind the zinc-containing active site. Lactotripeptides VPP and IPP have been commercialized in Japan and Finland with meta-analyses showing systolic reductions of 3–4 mmHg. These sequences survive simulated GI digestion and are absorbed intact via PepT1. Collagen-derived Gly-Pro sequences add ACE-i activity from meat sources.
β-Casomorphin-7 from A1 β-casein acts on μ-opioid receptors in the enteric nervous system, modulating gut motility, gastric emptying, and satiety — potentially synergistic with GLP-1 pathways. Gluten exorphins demonstrate similar enteric activity. Beyond opioid peptides: caseinophosphopeptides enhance mineral bioavailability, lactoferricin fragments show immunomodulatory properties, and secondary metabolites liberated during controlled proteolysis represent an expanding frontier we are actively characterizing.
Chlorian operates as a formulation engineering company. We design, model, and validate the co-administration systems that convert uncontrolled protein digestion into a precision bioactive liberation process. We do not manufacture end products — we engineer the formulations and the science behind them, then transfer the technology to partners who produce and distribute.
Our deliverable is a complete formulation architecture — validated from computational model through in vitro digestion to the data package required for regulatory positioning. Each formulation is matched to a specific protein source (beef, dairy, collagen, plant), a target bioactive axis (DPP-IV/GLP-1, ACE-i, opioid), and a defined use context. We specify every component: the pH buffering system, the viscosity modifier type and concentration, the competitive substrate composition, the ionic modulators for transporter optimization.
For partners developing regulated nutritional products — whether under EU FSMP frameworks, health claim regulations, or equivalent international pathways — we provide the scientific substantiation architecture: mechanistic rationale, in vitro evidence generated via INFOGEST 2.0 consensus protocol, Caco-2 transport data, and study designs for clinical validation. The regulatory strategy is part of the formulation — not an afterthought.
For nutraceutical and functional food companies seeking to incorporate bioactive peptide science into their product lines without building deep in-house GI biochemistry capability, we provide formulation design, optimization, and technology licensing.
Complete co-administration system architecture matched to protein source and therapeutic axis. Computational modeling through validated specification.
INFOGEST 2.0 static and semi-dynamic simulated digestion. LC-MS/MS peptidomics. Fractionated bioactivity assays (DPP-IV, ACE inhibition).
Caco-2 monolayer studies. PepT1 transport kinetics. Brush-border DPP-IV activity. GLP-1 secretion models (GLUTag, NCI-H716).
Scientific substantiation packages for FSMP, novel food, or health claim positioning. Study design for clinical endpoints. Dossier preparation.
IP licensing for proprietary formulation methods, competitive substrate systems, and digestive engineering techniques. Portfolio-level or single-formulation agreements.
Deep technical consulting on GI biochemistry, proteolytic cascade engineering, bioactive peptide development, and transporter pharmacology for biotech and pharma.
Design, modeling, and validation of co-administration systems that control digestive proteolysis for therapeutic peptide liberation. From computational model through INFOGEST-validated specification to technology transfer.
Defensible IP around digestive engineering methods, competitive substrate systems, formulation compositions. Complementary portfolio acquisition across bioactive peptide and GI engineering space.
Deep technical advisory for biotech, pharma, and food technology. GI biochemistry, proteolytic modeling, regulatory strategy, bioactive peptide programs, transporter pharmacology.
Corporate vehicle for strategic asset acquisition, venture formation, cross-sector technology transfer, and participation in decentralized science frameworks.
We treat biological systems as information-processing systems amenable to engineering. Every claim carries a confidence interval. We update on evidence, pre-register hypotheses, and expose full reasoning chains. The map-territory distinction is operational methodology.
Our formulation development borrows more from chemical engineering and computational biology than from traditional food science. We model the GI tract as a series of continuous stirred-tank reactors with variable parameters and simulate proteolytic cascades computationally before running INFOGEST protocols. The in silico model predicts which fragments survive each phase; the in vitro model validates. Only validated predictions advance to formulation lock.
We optimize for durable impact. We are not building a supplement brand. We are building the engineering layer between dietary protein intake and therapeutic peptide delivery — and licensing that capability to partners who build products.
Chlorian participates in the DeSci ecosystem — decentralized governance, token-aligned incentives, and on-chain IP frameworks to fund and coordinate research beyond traditional grant structures.